The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.

The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...

BOSTON -- Early cardiac resynchronization therapy (CRT) benefited patients with moderately reduced ejection fraction (EF) and left bundle branch block (LBBB) but no indication for pacing, according to ...

Study links exosomal microRNA to ventricular remodelling in heart failure. Discover how this biomarker could inform future ...

Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...

Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.